Clinical Trial Update: Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating biomarker analysis in castration-resistant prostate cancer patients treated with docetaxel followed by enzalutamide.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Instituto do Cancer do Estado de São Paulo | Conditions: Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING